A continuation of the CCOP grant will enable Hematology-Oncology Associates of Central New York, P.C. (HOACNY) to continue its active participation in a wide variety of ongoing clinical cancer research studies, including treatment and prevention trials. The goal of the program participation is to continue translating experience in cooperative group clinical research into expert cancer prevention, cancer control, diagnosis, and treatment (curative, palliative, supportive) for the greater community of central New York (Syracuse and surrounding rural counties). The Syracuse Hematology-Oncology CCOP aims to continue pursuing multi-disciplinary and multi-specialty participation in and awareness of clinical treatment and prevention protocols. The CCOP physicians and staff will continue in efforts to reach the professional and lay publics with current practice in the prevention and management of cancer and to encourage participation in research which has long term benefits for the entire community. The CCOP plans to increase recruitment of minorities to research trials and to maintain its high level of female participation in clinical trials. More specifically, the goal of the Syracuse CCOP physicians and staff is to maintain current levels of participation in clinical treatment trials while increasing the number of registrants on prevention and control trials. In the process of recruitment, the CCOP staff will be able to continue providing health education and screening related to cancer prevention and control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045389-12
Application #
2712610
Study Section
Special Emphasis Panel (SRC (74))
Program Officer
Dunn, Barbara K
Project Start
1987-07-21
Project End
1999-05-31
Budget Start
1998-06-08
Budget End
1999-05-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Hematology-Oncology Associates/Ctl NY
Department
Type
DUNS #
City
East Syracuse
State
NY
Country
United States
Zip Code
13057
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20

Showing the most recent 10 out of 66 publications